BeyondSpring (BYSI) Company Total Revenue

Strict FDA oversight and costly development contrast with the business's successful adaptation to US and Chinese standards. BeyondSpring Inc. overall sales levels demonstrate revenue dynamics, where the 0.00 mark reflects the current state of cash flow. High scalability driven by molecule patents allows BeyondSpring Inc. to effectively capture global markets by utilizing third-party drug synthesis.

BYSI - BeyondSpring Company Revenue over the range 07/04/2022 - 11/13/2026

Analytical breakdowns for BeyondSpring (BYSI)

- stock value and consensus price forecast:

Stock Quotes BeyondSpring Inc|BYSI - Price Target Chart

- market capitalization details:

Market Value BeyondSpring Inc.|BYSI - Total Company Value

- book value of equity indicators:

Net Assets per Single Share BeyondSpring|BYSI - Company Book Value|Market-to-Book Ratio beyondspringpharma.com|BYSI - Company Total Assets

- company liabilities and liquidity data:

- earnings and market ratios statistics:

BYSI - Net Profit|Expected Net Profit BeyondSpring Inc.|BYSI - Price to Earnings Ratio|Future Price to Earnings Multiple beyondspringpharma.com|BYSI - PEG Multiple|EV/EBITDA Multiple BeyondSpring Inc.|BYSI - Profit before payment of interest, taxes and amortization|Earnings per one share for the last 12 months BeyondSpring|BYSI - Net earnings per share for the last 12 months|Earnings per share growth in annualized terms for the last twelve months beyondspringpharma.com|BYSI - Earnings growth in current year|Net earnings per share growth forecast for next year BeyondSpring Inc.

- sales volume and revenue indicators:

BYSI - Revenue and Sales Volume|Company Expected Sales Volume BeyondSpring Inc|BYSI - Market Cap to Revenue|Market Cap to Future Revenue Ratio BeyondSpring Inc.

General company analysis:BeyondSpring Inc - BYSI

Mass-produced product of BeyondSpring Inc.

When analyzing the sales trajectory of BeyondSpring Inc. (BYSI), it is essential to consider the specifics of its oncology ecosystem and current FDA regulatory restrictions. This indicator captures the daily cash inflow from therapy sales, reflecting the company's actual revenue. The metric's calculation logic allows for a comparison between real cash receipts and management's long-term monetization plans for Plinabulin. The stability of this trend is critical for assessing business resilience amid the blocking of new markets.

Competing companies